CellaVision AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 08, 2023 at 02:33 am EST
Share
CellaVision AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 152.32 million compared to SEK 164.16 million a year ago. Net income was SEK 32.3 million compared to SEK 39.76 million a year ago. Basic earnings per share from continuing operations was SEK 1.35 compared to SEK 1.67 a year ago.
For the full year, sales was SEK 639.34 million compared to SEK 565.55 million a year ago. Net income was SEK 118.34 million compared to SEK 125.34 million a year ago. Basic earnings per share from continuing operations was SEK 4.96 compared to SEK 5.25 a year ago.
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
CELLAVISION AB 
